Get 40% Off
😲 Missed the +20.8% surge in our stock strategy last month? Not again! Get premium insightsGet 40% Off Now

Paladin Labs Inc. (PLB)

Toronto
Currency in CAD
Disclaimer
142.06
0.00(0.00%)
Closed
Fair Value
Unlock Value
Day's Range
140.90148.61
52 wk Range
0.00148.61
Bid/Ask
141.98 / 149.90
Prev. Close
142.06
Open
148
Day's Range
140.9-148.61
52 wk Range
0-0
Volume
0
Average Volume (3m)
510,066
1-Year Change
0%
Shares Outstanding
20,765,000
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about PLB?
Vote to see community's results!
or

Paladin Labs Inc. Company Profile

Paladin Labs Inc., researches, develops, acquires, in-licenses, markets, and distributes pharmaceutical products. It focuses on various therapeutic fields, such as urology, pain and central nervous system, women’s health, allergy, endocrinology, and dermatology. The company primarily offers Abstral for the management of breakthrough pain in patients with cancer; GlucaGen for emergency treatment of hypoglycemia in insulin-dependent diabetics; Oralair for the treatment of the symptoms of seasonal grass pollen allergic rhinitis; and Metadol for use as an analgesic in acute cancer pain, palliative care, and chronic pain disorders, as well as for the detoxification or maintenance treatment of opioid-dependent individuals. Its principal products also include Plan B (Levonorgestrel), an emergency contraceptive; Pollinex-R for the pre-seasonal immunotherapy of adults and children; Seasonale, an oral contraceptive; Silenor for the treatment and symptomatic relief of insomnia; Testim for testosterone replacement therapy in adult males; Twinject, a pre-filled auto-injector for emergency treatment of severe allergic reactions; and Tridural for moderate to moderately severe pain. In addition, the company researches and develops pharmaceuticals and medical devices as well as supplies vaccines to South Africa and countries comprising the South African Development Community region. Paladin Labs Inc. was formerly known as Geriatrx Pharmaceutical Corp. and changed its name to Paladin Labs Inc. in June 1995. The company was founded in 1983 and is headquartered in St-Laurent, Canada. As of February 28, 2014, Paladin Labs Inc. operates as a subsidiary of Paladin Labs Canadian Holding Inc. On August 16, 2022, Paladin Labs Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. It is in joint administration with Endo International plc.

Employees
403
Market
Canada
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.